Services
life span extension
With in-depth knowledge of cellular senescence and mechanisms to overcome this irreversible growth arrest, Evercyte offers the development of human cell lines that can be grown without limitations while maintaining a phenotype similar to the corresponding normal cells. Besides ectopic expression of the catalytic subunit of human telomerase (hTERT) or regulators of cell cycle control pathways, Evercyte has also established protocols to reprogram cells towards induced pluripotent stem cells (iPSCs) that can give rise to theoretically any cell type of the human organism.
General information
Tissue, cell type: Evercyte offers the immortalization / life span extension of different human cell types (e.g. fibroblasts from skin, lung, kidney tissue, keratinocytes, endothelial cells from skin, umbilical vein or mesenchymal stem cells from adipose tissue, placental tissue or bone marrow)
Recent example – immortalization of mesenchymal stromal cells
Wharton´s Jelly-derived mesenchymal stromal cells were isolated from umbilical cord tissue using enzymatic and mechanical disaggregation. After enrichment, the normal cells were transfected with a plasmid carrying the catalytic subunit of human telomerase (hTERT) and transfectants were selected by growing cells in the presence of Geneticin sulfate (G418). The resulting cell line can be grown for a minimum of 50 population doublings with a stable growth rate without showing signs of growth retardation. The cells are characterized by the typical spindle-shaped mesenchymal morphology and express typical markers and functions of mesenchymal stromal cells (not shown).
Recent example – reprogramming of urine cells into iPSCs
Evercyte has developed protocols for isolation of different cells (e.g. renal proximal tubular epithelial cells, podocytes, urine-stem cells, mesenchymal stromal cells) from human urine sediments. These cells are reprogrammed into induced pluripotent stem cells (iPSCs) that can be differentiated towards cells from the 3 germ layers such as muscle cells, neuronal cells or hepatocyte-like cells.
FAQs
Leaflets - telomerized cells
Selected publications
Schrom S, Kleinegger F, Anders I, Hebesberger T, Karner C, Liesinger L, Birner-Gruenberger R, Renner W, Pichler M, Grillari R, Aigelsreiter A, Rinner B. MUG CCArly: A Novel Autologous 3D Cholangiocarcinoma Model Presents an Increased Angiogenic Potential. Cancers (Basel). 2023 Mar 14;15(6):1757. doi: 10.3390/cancers15061757. https://pubmed.ncbi.nlm.nih.gov/36980644/
(2011) Generation of induced pluripotent stem cells from urine. J Am Soc Nephrol. 2011 Jul;22(7):1221-8. https://pubmed.ncbi.nlm.nih.gov/33717998/
Generation of human induced pluripotent stem cells from urine samples. Nat Protoc. 2012 Dec;/(12):2080-9. https://pubmed.ncbi.nlm.nih.gov/23138349/
Customer Reviews
“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”
Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.
"Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform. We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed."
Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.
Customer Reviews
“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”
Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.
"Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform. We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed."
Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.
